Form 4: Fennec Pharmaceuticals CFO Receives Stock Options and Restricted Share Units

Robert Andrade, CFO of Fennec Pharmaceuticals, was granted stock options and restricted share units on March 28, 2025, according to a Form 4 filing.

Summary

• Robert Andrade, the CFO of Fennec Pharmaceuticals, received an award of 75,000 restricted share units on March 28, 2025, under the company's 2020 Equity Incentive Plan.
• These shares will vest over time, starting with one-third on March 28, 2026, and then incrementally each month until February 29, 2028, when all shares will be fully vested.
• Andrade also received incentive stock options to purchase 50,000 shares of Fennec Pharmaceuticals' common stock at an exercise price of $6.50 per share.
• These options also vest over time, beginning with one-third on March 28, 2026, and then incrementally each month until February 29, 2028, when all options will be fully vested.
• Following these transactions, Andrade directly owns 827,722 common shares and has options for 877,722 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity aligns management interests with shareholders, which is generally viewed favorably. There are no indications of negative news or concerns.

Positives

• The granting of stock options and restricted share units aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Equity grants are a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and restricted share unit grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans to align executive interests with shareholder value.
• The vesting schedules are typical, designed to encourage long-term commitment and performance.

Stakeholder Impact

• The equity grants could potentially increase shareholder value if the CFO's performance leads to company growth.
• The grants incentivize the CFO to make decisions that benefit the company's long-term success.

Key Dates

Keywords

Fennec Pharmaceuticals, Robert Andrade, CFO, stock options, restricted share units, equity incentive plan, Form 4, vesting